Logos Global Management’s KalVista Pharmaceuticals KALV Stock Holding History

Logos Global Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-900,000	Closed	-$8.67M	–	61
2023 Q3	$8.67M	Buy	+900,000	New	+$9.2M	1.16%	28
2021 Q1	–	Sell	-490,000	Closed	-$9.3M	–	63
2020 Q4	$9.3M	Buy	490,000 +190,000	+63%	+$3.26M	0.8%	27
2020 Q3	$3.78M	Sell	300,000 -262,900	-47%	-$3.29M	0.48%	35
2020 Q2	$6.81M	Buy	+562,900	New	+$5.99M	1.36%	27

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Logos Global Management's KALV Position: Q4 2023 in Review

Logos Global Management sold out of KalVista Pharmaceuticals (KALV) in Q4 2023, closing a stake of 900,000 shares — an estimated $8.67M sold.

Logos Global Management first reported a position in KALV in Q2 2020 and held it in 4 quarters. The position peaked at $9.3M in Q4 2020. 93 funds tracked by Wall St. Rank hold KALV as of Q4 2023.

Logos Global Management reported no remaining KalVista Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Logos Global Management sold 900,000 KalVista Pharmaceuticals shares in Q4 2023, an estimated $8.67M.
Logos Global Management first reported a position in KalVista Pharmaceuticals in Q2 2020 and held it in 4 quarters.
Logos Global Management's KalVista Pharmaceuticals position peaked at $9.3M in Q4 2020.
93 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2023.

Based on Logos Global Management's 13F filing for Q4 2023, filed 14 Feb 2024.